Polygenic Score (PGS) ID: PGS000736

Predicted Trait
Reported Trait QRS duration
Mapped Trait(s) QRS duration (EFO_0005055)
Released in PGS Catalog: Feb. 23, 2021
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name PRS_QRS
Development Method
Name Genome-wide significant variants
Parameters NR
Variants
Original Genome Build GRCh37
Number of Variants 26
Effect Weight Type beta
PGS Source
PGS Catalog Publication (PGP) ID PGP000144
Citation (link to publication) Tadros R et al. Eur Heart J (2019)
Ancestry Distribution
Source of Variant
Associations (GWAS)
European: 100%
60,255 individuals (100%)
PGS Evaluation
European: 100%
4 Sample Sets

Development Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry Cohort(s)
GWAS Catalog: GCST003844
Europe PMC: 27659466
 60,255 individuals European 24 cohorts
  • AGES
  • ,ARIC
  • ,BRIGHT
  • ,CHS
  • ,CROATIA-KORCULA
  • ,CROATIA-SPLIT
  • ,ERF
  • ,FHS
  • ,INGI-Cilento
  • ,INGI-FVG
  • ,InCHIANTI
  • ,KORA
  • ,LOLIPOP
  • ,LifeLines
  • ,MESA
  • ,MICROS
  • ,ORCADES
  • ,PREVEND
  • ,PROSPER
  • ,RS
  • ,SHIP
  • ,SardiNIA
  • ,TwinsUK
  • ,YFS

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM) 		PGS Sample Set ID
(PSS) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM001760 PSS000905|
European Ancestry|
1,185 individuals
 PGP000144 |
Tadros R et al. Eur Heart J (2019)
 Reported Trait: Ajmaline-induced Type I Brugada syndrome electrocardiogram OR: 1.047 [1.031, 1.063] — — — —
PPM001753 PSS000906|
European Ancestry|
1,193 individuals
 PGP000144 |
Tadros R et al. Eur Heart J (2019)
 Reported Trait: QRS slope in non SCN5A mutation carriers β: 0.93 (0.2) — Correlation coefficient (r): 0.14 — —
PPM001751 PSS000906|
European Ancestry|
1,193 individuals
 PGP000144 |
Tadros R et al. Eur Heart J (2019)
 Reported Trait: Baseline QRS in non SCN5A mutation carriers — — Correlation coefficent (r): 0.15 — —
PPM001755 PSS000904|
European Ancestry|
1,257 individuals
 PGP000144 |
Tadros R et al. Eur Heart J (2019)
 Reported Trait: QRS slope β: 0.8 (0.22) — — — —
PPM001756 PSS000903|
European Ancestry|
295 individuals
 PGP000144 |
Tadros R et al. Eur Heart J (2019)
 Reported Trait: QRS slope β: 0.8 (0.22) — — Age, SCN5A mutation —

Evaluated Samples

PGS Sample Set ID
(PSS) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000903 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.14 — 295 individuals — European — Amsterdam —
PSS000904 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.12 — 1,257 individuals — European — Amsterdam —
PSS000905 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.15 — 1,185 individuals — European — Amsterdam —
PSS000906 Intravenous ajmaline was administered at consecutive boluses of 10 mg/min. A 10-s ECG was recorded ∼1 min after each bolus using a GE Healthcare electrocardiograph. The test was stopped when the target dose of 1 mg/kg rounded up to the next 10 mg was reached, if ventricular arrhythmia occurred, or at the manifestation of a Type I BrS pattern, defined as an ST elevation >2 mm with a coved morphology in any lead among V1–V2 in the 2nd to 4th intercostal spaces.13 — 1,193 individuals — European — Amsterdam —